| Title |
Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
|
|---|---|
| Published in |
Cancer Management and Research, April 2018
|
| DOI | 10.2147/cmar.s142269 |
| Pubmed ID | |
| Authors |
Thomas C Weart, Kenneth D Miller, Charles B Simone |
| Abstract |
Advanced non-small-cell lung cancer (NSCLC) remains a challenging disease. The limited utility of chemotherapy indicates the need for additional therapeutic options. Targeted therapy continues to be an important tool in the treatment of NSCLC. Mutations within the RAS-RAF-MEK-MAPK pathway, specifically the BRAF V600E mutation, have become an important target for the subset of NSCLC patients with this mutation. This paper summarizes the clinical evidence that lead to the recent approval of the combination of dabrafenib and trametinib to treat patients with advanced NSCLC who harbor a BRAF V600E mutation. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 31 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 19% |
| Other | 4 | 13% |
| Student > Ph. D. Student | 4 | 13% |
| Researcher | 3 | 10% |
| Student > Master | 2 | 6% |
| Other | 4 | 13% |
| Unknown | 8 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 10 | 32% |
| Medicine and Dentistry | 5 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 13% |
| Nursing and Health Professions | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 9 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 April 2018.
All research outputs
#17,438,425
of 25,584,565 outputs
Outputs from Cancer Management and Research
#786
of 2,067 outputs
Outputs of similar age
#222,517
of 344,304 outputs
Outputs of similar age from Cancer Management and Research
#24
of 57 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,067 research outputs from this source. They receive a mean Attention Score of 3.5. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 344,304 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.